{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:48:43Z","timestamp":1790045323880,"version":"4.0.1"},"reference-count":70,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.2217\/fmb-2018-0067","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T08:15:17Z","timestamp":1526458517000},"page":"1081-1094","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Delafloxacin: An Improved Fluoroquinolone Developed through Advanced Molecular Engineering"],"prefix":"10.1080","volume":"13","author":[{"given":"Matteo","family":"Bassetti","sequence":"first","affiliation":[{"name":"Department of Medicine,Infectious Diseases Clinic,University of Udine School of Medicine,Santa Misericordia University Hospital,\rUdine,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elda","family":"Righi","sequence":"additional","affiliation":[{"name":"Department of Medicine,Infectious Diseases Clinic,University of Udine School of Medicine,Santa Misericordia University Hospital,\rUdine,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Pecori","sequence":"additional","affiliation":[{"name":"Department of Medicine,Infectious Diseases Clinic,University of Udine School of Medicine,Santa Misericordia University Hospital,\rUdine,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Tillotson","sequence":"additional","affiliation":[{"name":"GST Micro LLC,\rDurham,\rNC\r27713,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"Saxon W . Anne Miller 90 first patient who was saved by penicillin . The New York Times . www.nytimes.com\/1999\/06\/09\/us\/anne-miller-90-first-patient-who-was-saved-by-penicillin.html ."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2014.1570"},{"key":"e_1_3_2_5_1","unstructured":"WHO| WHO publishes list of bacteria for which new antibiotics are urgently needed . www.who.int\/mediacentre\/news\/releases\/2017\/bacteria-antibiotics-needed\/en\/ ."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.9.3383"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.64.5.591"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.11.926"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.6.7767510"},{"issue":"2","key":"e_1_3_2_10_1","first-page":"79","article-title":"The pH of secretions in sinusitis and otitis media","volume":"22","author":"Nuutinen J","year":"1993","unstructured":"Nuutinen J , TorkkeliT , PenttilaI . The pH of secretions in sinusitis and otitis media . Am. J. Otolaryngol.22 ( 2 ), 79 \u2013 82 ( 1993 ).","journal-title":"Am. J. Otolaryngol."},{"key":"e_1_3_2_11_1","first-page":"153","article-title":"Laboratory studies on gentamicin","volume":"161","author":"Rubenis M","year":"1963","unstructured":"Rubenis M , KozijVM , JacksonGG . Laboratory studies on gentamicin . Antimicrob. Agents Chemother. (Bethesda)161 , 153 \u2013 156 ( 1963 ).","journal-title":"Antimicrob. Agents Chemother. (Bethesda)"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1983.127.1.39"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-005-8206-y"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501881c"},{"issue":"2","key":"e_1_3_2_15_1","first-page":"161","article-title":"[The history of the development and changes of quinolone antibacterial agents]","volume":"38","author":"Takahashi H","year":"2003","unstructured":"Takahashi H , HayakawaI , AkimotoT . [The history of the development and changes of quinolone antibacterial agents] . Yakushigaku zasshi38 ( 2 ), 161 \u2013 179 ( 2003 ).","journal-title":"Yakushigaku zasshi"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2002\/864789"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1987.tb04030.x"},{"issue":"2","key":"e_1_3_2_18_1","first-page":"105","article-title":"Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials","volume":"6","author":"Nix DE","year":"1987","unstructured":"Nix DE , DevitoJM . Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials . Clin. Pharm.6 ( 2 ), 105 \u2013 117 ( 1987 ).","journal-title":"Clin. Pharm."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg212"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg208"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.11.082"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10359"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03991.x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.04.007"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.427"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.799-803.2004"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.4.593"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.8.663.33201"},{"key":"e_1_3_2_29_1","unstructured":"Glaxo Wellcome Press Release . 27 October 1999 . http:\/\/apps.who.int\/medicinedocs\/en\/d\/Jh1461e\/5.8.html#Jh1461e.5.8 . Accessed April 13 2018 ."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130165"},{"key":"e_1_3_2_31_1","unstructured":"European Medicines Agency . Public statement on Trovan\/Trovan IV\/Turvel\/Turvel IV (Trovafloxacin\/Alatrofloxacin) recommendation to suspend the marketing authorisation in the European Union . www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2009\/12\/news_detail_000923.jsp&mid=WC0b01ac058004d5cf ."},{"issue":"1","key":"e_1_3_2_32_1","first-page":"29","article-title":"Crystal-induced acute kidney injury due to ciprofloxacin","volume":"4","author":"Khan M","year":"2015","unstructured":"Khan M , OrtegaLM , BagwanN , NayerA . Crystal-induced acute kidney injury due to ciprofloxacin . J. Nephropathol.4 ( 1 ), 29 \u2013 31 ( 2015 ).","journal-title":"J. Nephropathol."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-2-170_1"},{"issue":"2","key":"e_1_3_2_34_1","first-page":"75","article-title":"Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature","volume":"32","author":"Hootkins R","year":"1989","unstructured":"Hootkins R , FenvesAZ , StephensMK . Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature . Clin. Nephrol.32 ( 2 ), 75 \u2013 78 ( 1989 ).","journal-title":"Clin. Nephrol."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mop.0000192520.48411.fa"},{"issue":"4","key":"e_1_3_2_36_1","first-page":"535","article-title":"Safety of the new quinolones in pregnancy","volume":"84","author":"Berkovitch M","year":"1994","unstructured":"Berkovitch M , PastuszakA , GazarianM , LewisM , KorenG . Safety of the new quinolones in pregnancy . Obstet. Gynecol.84 ( 4 ), 535 \u2013 538 ( 1994 ).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1085968"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12228"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.05.027"},{"key":"e_1_3_2_40_1","unstructured":"FDA approves safety labeling changes for fluoroquinolones . www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm500325.htm ."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2050"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S106071"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0198-x"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks307"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02798-15"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.39"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00941-16"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1041"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.817"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00772-17"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.094"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.11.019"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1042946"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1386654"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.04.009"},{"key":"e_1_3_2_57_1","unstructured":"Baxdela\u2122 prescribing information . Melinta Therapeutics IL USA . www.baxdela.com\/docs\/baxdela-prescribing-information.pdf ."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh242"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00647-16"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1071-0"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.14.1585"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2017.1279519"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05817-11"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.145"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.10.009"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv411"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx329"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165"},{"key":"e_1_3_2_69_1","unstructured":"Giordano P NseirW LawrenceL YangL CammarataS . Delafloxacin (DLX) is effective and well-tolerated in treatment of diabetic (DM) patients with acute bacterial skin and skin structure infections (ABSSSI) versus vancomycin\/aztreonam (VAN\/AZ) ( 2017 ). file:\/\/\/Users\/christine\/Downloads\/P1353_abstract.pdf ."},{"key":"e_1_3_2_70_1","volume-title":"55th Interscience Conference on Antimicrob. Agents Chemother. (ICAAC)","author":"Ferguson J","year":"2010","unstructured":"Ferguson J , LawrenceL , PaulsonS , SchlosserMJ , CammarataS . Assessment of phototoxicity potential of delafloxacin in healthy male and female subjects: a Phase I study . Presented at : 55th Interscience Conference on Antimicrob. Agents Chemother. (ICAAC) . San Diego, CA, USA , 17\u201321 September (2010) ."},{"key":"e_1_3_2_71_1","unstructured":"Clinical Trials Database: NCT02015637 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02015637 ."},{"key":"e_1_3_2_72_1","unstructured":"Melinta Therapeutics ceases Phase III proceeding study . http:\/\/ir.melinta.com\/news-releases\/news-release-details\/melinta-therapeutics-ceases-phase-3-proceeding-study ."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2018-0067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:03Z","timestamp":1719124683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2018-0067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.2217\/fmb-2018-0067"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2018-0067","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}